Skip to content
Assyro AI
Back to Glossary
Submission & Approval

Fast Track Designation

Fast Track Designation is an FDA status, granted on sponsor request, that expedites development and review of a drug for a serious or life-threatening condition demonstrating potential to address an unmet medical need.

Usage Examples

  • We are filing the Fast Track request with the original IND so the meeting cadence starts before the Phase 2 design locks.
  • Fast Track gets us rolling review, but the review goal does not start running until the last module lands.
  • The designation is per indication, so the second program needs its own Fast Track request.

What is Fast Track Designation?

Fast Track Designation is an FDA status, granted on sponsor request, that expedites development and review of a drug for a serious or life-threatening condition demonstrating potential to address an unmet medical need.

Fast Track Designation exists because a drug for a serious condition gains nothing from a fast review if the development program took ten years and answered the wrong question. Congress made expedited development a statutory duty rather than an FDA courtesy: on the sponsor's request, the agency shall facilitate the development and expedite the review of a qualifying drug.

Fast Track Designation covers drugs and biologics clearing two independent tests: intended treatment of a serious or life-threatening disease or condition, and demonstrated potential to address an unmet medical need for that condition. It attaches to that drug-condition pair, not the molecule generally. It does not cover devices, lower the approval standard, or by itself shorten the review goal.

Fast Track Designation is applied through the request letter and everything that follows it. Sponsors file concurrently with the IND or later, FDA answers within 60 calendar days, and the designation then buys development-stage access and, at the end, rolling review. Rolling review requires a submission schedule agreed with FDA and payment of the application fee before any portion is reviewed.

Not to be confused with

Breakthrough Therapy
Breakthrough requires preliminary clinical evidence that the drug may show substantial improvement over existing therapies. Fast Track requires only potential to address an unmet need, so it can be granted before any human data exists.
Accelerated Approval
Accelerated Approval is an approval basis, resting on a surrogate or earlier clinical endpoint reasonably likely to predict benefit. Fast Track is a designation; it changes how you reach the application, not what evidence supports approval.
Priority Review
Priority Review compresses FDA's review goal after the application is filed. Fast Track does not compress it; the statute suspends the agreed goal until a rolling submission is complete.
Rolling review
Rolling review is one feature available to a fast track product, not a synonym for the designation. It needs a separate FDA determination that the product may be effective, plus an agreed completion schedule and the fee.

The obligations sit in the statute; the CFR governs the development-stage interactions around it.

What you must do

  1. 1Establish both statutory prongs in the request: intended treatment of a serious or life-threatening disease or condition, and potential to address an unmet medical need for that condition21 U.S.C. 356(b)(1)
  2. 2File the designation request concurrently with, or at any time after, the IND submission21 U.S.C. 356(b)(2)
  3. 3Plan the program around a determination arriving within 60 calendar days of FDA's receipt of the request21 U.S.C. 356(b)(2)
  4. 4Before FDA will commence a rolling review, provide a schedule for submission of the information needed to complete the application and pay the required application fee21 U.S.C. 356(d)(1)
  5. 5Do not schedule launch off the agreed review goal during a rolling submission; that goal does not apply until the date the application is complete21 U.S.C. 356(d)(2)
  6. 6Route development-stage interactions through part 312 subpart E, which exists to expedite the development, evaluation, and marketing of drugs for life-threatening and severely-debilitating illnesses21 CFR 312.80

Common mistakes

  • Requesting Fast Track late in Phase 3

    The designation's value is concentrated in development-stage interaction, and once the pivotal trial is enrolling, the design decisions it was supposed to influence are already made. The request still consumes 60 days of agency and internal effort and changes nothing about the program.

  • Selling Fast Track as a faster approval

    It is neither a lower evidentiary bar nor a shorter review goal. Boards and investors told the designation buys speed to market create a credibility problem when the review takes exactly as long as it otherwise would have.

  • Starting a rolling submission without the schedule and fee in place

    FDA commences review of portions only after the applicant provides a completion schedule and pays the application fee. Sponsors who ship Module 3 early without that agreement get no review credit and lose the sequencing advantage the whole plan depended on.

When This Matters

  • We are filing the Fast Track request with the original IND so the meeting cadence starts before the Phase 2 design locks.
  • Fast Track gets us rolling review, but the review goal does not start running until the last module lands.
  • The designation is per indication, so the second program needs its own Fast Track request.

Frequently Asked Questions

Fast Track requires two things at once: the drug must be intended to treat a serious or life-threatening disease or condition, and it must demonstrate potential to address an unmet medical need for that condition. Both prongs come from 21 U.S.C. 356(b)(1). Because the request may be filed concurrently with the IND, clinical data is not a prerequisite.

Related Use Cases

Related Regulatory Intelligence

Related Actions

Sources & References

Share this page
Agent CTA Background

Simplify Fast Track compliance

Book a Demo